BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 285 filers reported holding BIO-TECHNE CORP in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,477,215 | +438.7% | 168,609 | +546.0% | 0.23% | +461.0% |
| Q2 2023 | $2,130,461 | -58.8% | 26,099 | +127.4% | 0.04% | -54.9% |
| Q2 2021 | $5,167,000 | -50.6% | 11,475 | -58.1% | 0.09% | -53.3% |
| Q1 2021 | $10,452,000 | -3.1% | 27,365 | -19.4% | 0.20% | -4.4% |
| Q4 2020 | $10,784,000 | +28.2% | 33,960 | +0.0% | 0.20% | +15.3% |
| Q3 2020 | $8,412,000 | -6.2% | 33,955 | 0.0% | 0.18% | -14.1% |
| Q2 2020 | $8,966,000 | +34.8% | 33,955 | -3.2% | 0.21% | +9.6% |
| Q1 2020 | $6,649,000 | -13.6% | 35,065 | 0.0% | 0.19% | +16.0% |
| Q4 2019 | $7,697,000 | +12.2% | 35,065 | -0.0% | 0.16% | +4.5% |
| Q3 2019 | $6,862,000 | -6.2% | 35,070 | 0.0% | 0.16% | -4.9% |
| Q2 2019 | $7,312,000 | +4.9% | 35,070 | -0.1% | 0.16% | -1.2% |
| Q1 2019 | $6,969,000 | +36.9% | 35,100 | -0.2% | 0.16% | +24.1% |
| Q4 2018 | $5,090,000 | -30.1% | 35,175 | -1.5% | 0.13% | -16.4% |
| Q3 2018 | $7,285,000 | +32.3% | 35,695 | -4.1% | 0.16% | +23.3% |
| Q2 2018 | $5,508,000 | -8.2% | 37,230 | -6.3% | 0.13% | -5.1% |
| Q1 2018 | $6,000,000 | +16.3% | 39,730 | -0.2% | 0.14% | +21.4% |
| Q4 2017 | $5,159,000 | +7.2% | 39,825 | 0.0% | 0.11% | +4.7% |
| Q3 2017 | $4,814,000 | +2.4% | 39,825 | -0.5% | 0.11% | +1.9% |
| Q2 2017 | $4,701,000 | +15.6% | 40,015 | 0.0% | 0.10% | +14.1% |
| Q1 2017 | $4,067,000 | +4.0% | 40,015 | +5.3% | 0.09% | +5.7% |
| Q4 2016 | $3,909,000 | -5.1% | 38,015 | +1.0% | 0.09% | -3.3% |
| Q3 2016 | $4,121,000 | -51.4% | 37,640 | -50.0% | 0.09% | +4.7% |
| Q2 2016 | $8,488,000 | +138.6% | 75,280 | +100.0% | 0.09% | +19.4% |
| Q1 2016 | $3,557,000 | +6.1% | 37,640 | +1.1% | 0.07% | +14.3% |
| Q4 2015 | $3,351,000 | +80.3% | 37,235 | +85.2% | 0.06% | +80.0% |
| Q3 2015 | $1,859,000 | -6.4% | 20,110 | -0.3% | 0.04% | 0.0% |
| Q2 2015 | $1,986,000 | -1.8% | 20,175 | 0.0% | 0.04% | -7.9% |
| Q1 2015 | $2,023,000 | +8.5% | 20,175 | 0.0% | 0.04% | 0.0% |
| Q4 2014 | $1,864,000 | – | 20,175 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |